Democratic People's Republic of KoreaTuberculosis profile
Population  2014 25 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5 (2–9.3) 20 (7.9–37)
Mortality (HIV+TB only) 0.021 (0.015–0.028) 0.08 (0.06–0.11)
Prevalence  (includes HIV+TB) 140 (38–300) 552 (150–1 210)
Incidence  (includes HIV+TB) 110 (100–120) 442 (412–473)
Incidence (HIV+TB only) 0.31 (0.25–0.38) 1.2 (0.99–1.5)
         
Case detection, all forms (%) 93 (87–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.8–3.9) 15 (8.8–24)
MDR-TB cases among notified pulmonary
TB cases
1 400 (610–3 000) 2 400 (1 400–3 800)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 34 622   8 413
Pulmonary, clinically diagnosed 41 423   0
Extrapulmonary 18 587   0
       
Total new and relapse 103 045    
Previously treated, excluding relapses 7 245    
Total cases notified 110 290    
Among 94 632 new cases:
5 631 (6%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 81 (<1%) 364 (2%) 445
Laboratory-confirmed RR-/MDR-TB cases     197
Patients started on MDR-TB treatment ***     212
TB/HIV 2014 Number (%)
TB patients with known HIV status 0 (0)
HIV-positive TB patients 0  
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (92) 97 665
Previously treated cases, excluding relapse, registered in 2013 (83) 7 247
HIV-positive TB cases, all types, registered in 2013   0
RR-/MDR-TB cases started on second-line treatment in 2012 (86) 50
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 27
% Funded domestically 20%
% Funded internationally 33%
% Unfunded 48%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-10-01 Data: www.who.int/tb/data